Tags : Five

Sarepta Signs a Two-Year Research and Option Agreement with Codiak

Shots: Codiak to receive up to $72.5M upfront, near-term license payments along with research funding and is eligible to receive development and regulatory milestone payments and tiered royalties on future sales of therapies emerges during the collaboration Sarepta gets an exclusive option to license Codiak’s technology to develop and commercialize engineered exosome therapies for up […]Read More

GSK Signs a Five Years Collaboration with Lyell to Develop

Shots: Lyell to apply its technologies to strengthen GSK’s cell therapy pipeline including GSK3377794 targeting the NY-ESO-1 antigen expressed along multiple cancer plus an approach to counter T cell exhaustion while increasing probability for delivering cancer therapies The focus of the agreement is to combine the GSK’s strong cell and gene therapy programmes with Lyell’s […]Read More

Pfizer’s Zirabev (biosimilar, bevacizumab) Receives the US FDA’s Approval for

Shots: The approval is based on REFLECTIONS B7391003 study results assessing Zirabev vs reference product Avastin, in patients with advanced non-sq NSCLC The study resulted in biosimilarity data, showing clinical equivalence and no clinically meaningful differences with the reference product in patients. Additionally, Zirabev is Pfizer’s second oncology biosimilar following Trazimera (trastuzumab-qyyp) Zirabev (bevacizumab-bvzr) is […]Read More

Crown Laboratories Acquires Rights for GSK’s Five OTC Drugs

  Crown to get North American rights of GSK’s OTC drugs namely, PanOxyl, Sarna, Zeasorb, Desenex, Mineral Ice The focus of the acquisition is to build Crown’s footprints in North America with expansion of its consumer portfolio to treat multiple conditions Products with indication: PanOxyl is an acne wash, Sarna is an anti-itch lotion, Zeasorb […]Read More